GeneDx Holdings Corp. (NASDAQ:WGS) Receives $87.43 Consensus Price Target from Brokerages

GeneDx Holdings Corp. (NASDAQ:WGS) has received an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $87.4286.

A number of research analysts have issued reports on the stock. Zacks Research raised shares of GeneDx from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Guggenheim reaffirmed a “buy” rating and set a $74.00 price target (up from $70.00) on shares of GeneDx in a report on Monday, June 29th. Wall Street Zen downgraded GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Canaccord Genuity Group set a $75.00 price objective on GeneDx and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Finally, TD Cowen reissued a “buy” rating on shares of GeneDx in a report on Wednesday, July 15th.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Analyst sentiment improved: Zacks Research raised its rating on GeneDx from “Strong Sell” to “Hold,” which may be supporting the stock by reducing some negative analyst pressure. Zacks Research
• Neutral Sentiment: Class-action deadline approaches: Multiple law firms, including Faruqi & Faruqi, Hagens Berman, Robbins Geller, Rosen Law Firm, and ClaimsFiler, reminded investors that August 3, 2026 is the deadline to seek lead-plaintiff status in a securities lawsuit against GeneDx. The notices largely repeat previously reported information rather than announcing a new court ruling or company development. Faruqi class-action deadline reminder
• Negative Sentiment: Litigation highlights business risks: The lawsuit filings allege that GeneDx and certain officers misrepresented acquisition performance and failed to disclose deteriorating reimbursement rates and margin compression. One investor notice points to an alleged decline from a $51 million acquisition expectation to a $31.2 million write-off and a roughly 49% stock decline during the class period. These are allegations, not established findings, but continued legal coverage could weigh on sentiment and create potential financial, reputational, and disclosure risks for GeneDx. Levi and Korsinsky lawsuit notice

GeneDx Price Performance

WGS stock opened at $68.96 on Tuesday. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38. GeneDx has a 52-week low of $32.21 and a 52-week high of $170.87. The stock’s 50 day moving average is $60.32 and its two-hundred day moving average is $69.97. The company has a market capitalization of $2.05 billion, a PE ratio of -25.73 and a beta of 1.90.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, May 4th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The business had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. During the same quarter last year, the company posted ($0.23) earnings per share. Analysts predict that GeneDx will post -1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Keith A. Meister acquired 533,758 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The shares were acquired at an average cost of $37.86 per share, for a total transaction of $20,208,077.88. Following the completion of the purchase, the director directly owned 3,761,908 shares in the company, valued at $142,425,836.88. This trade represents a 16.53% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Casdin Capital, Llc acquired 185,000 shares of GeneDx stock in a transaction that occurred on Tuesday, May 19th. The stock was bought at an average cost of $42.60 per share, with a total value of $7,881,000.00. Following the acquisition, the director directly owned 3,367,164 shares of the company’s stock, valued at approximately $143,441,186.40. This trade represents a 5.81% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have acquired 2,256,420 shares of company stock valued at $93,144,340 and have sold 19,135 shares valued at $1,128,499. Insiders own 25.17% of the company’s stock.

Hedge Funds Weigh In On GeneDx

Several large investors have recently bought and sold shares of the stock. Sumitomo Mitsui Trust Group Inc. lifted its position in GeneDx by 30.6% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 381,725 shares of the company’s stock worth $49,647,000 after purchasing an additional 89,470 shares during the period. SG Americas Securities LLC lifted its position in shares of GeneDx by 937.3% during the 4th quarter. SG Americas Securities LLC now owns 63,181 shares of the company’s stock valued at $8,217,000 after acquiring an additional 57,090 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of GeneDx by 4.5% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock valued at $158,738,000 after purchasing an additional 52,322 shares during the period. Vanguard Group Inc. raised its holdings in GeneDx by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock worth $154,650,000 after buying an additional 18,647 shares during the period. Finally, Renaissance Group LLC purchased a new stake in shares of GeneDx in the 4th quarter valued at approximately $7,167,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.